Filtered By:
Source: The American Journal of Cardiology
Condition: Thrombosis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 75 results found since Jan 2013.
Meta-Analysis of Anticoagulation Use, Stroke, Thromboembolism, Bleeding, and Mortality in Patients With Atrial Fibrillation on Dialysis
Atrial fibrillation (AF) is common in patients on dialysis. Although randomized trials of anticoagulation for AF have demonstrated striking reductions in stroke, these trials did not recruit patients on dialysis. We thus undertook this systematic review and meta-analysis of observational studies including patients with AF on dialysis that reported associations of anticoagulation use. Twenty studies involving 529,741 subjects and 31,321 patients with AF on dialysis were identified. Anticoagulation was associated with a 45% (95% CI 13% to 88%) increased risk of any stroke, reflecting a nonsignificant 13% (95% CI −4% to 34...
Source: The American Journal of Cardiology - April 12, 2016 Category: Cardiology Authors: Christopher X. Wong, Ayodele Odutayo, Connor A. Emdin, Ned J. Kinnear, Michelle T. Sun Tags: Arrhythmias and Conduction Disturbances Source Type: research
Meta-Regression to Identify Patients Deriving the Greatest Benefit from Dual Antiplatelet Therapy After Stroke or Transient Ischemic Attack Without Thrombolytic or Thrombectomy Treatment
The patient's profile drawing the greatest benefit from dual antiplatelet therapy (DAPT) after a non-cardioembolic, ischemic cerebrovascular event is not well characterized. Aim of this meta-regression analysis was to compare DAPT versus single antiplatelet therapy (SAPT) in patients with stroke or transient ischemic attack (TIA). We searched randomized trials evaluating clinical outcome with aspirin plus a P2Y12 inhibitor versus SAPT in patients with non-cardioembolic stroke or TIA. Primary endpoint was the incidence of recurrent stroke; safety outcome measure was major bleeding.
Source: The American Journal of Cardiology - May 24, 2019 Category: Cardiology Authors: Giuseppe Patti, Alessandro Sticchi, Antonio Bisignani, Francesco Pelliccia, Vincenzo Pasceri, Giulio Speciale, Maria Penco Source Type: research
Response to Readers ’ Comments “Effect of Anticoagulation Duration on Stroke Incidence in Asian Patients With Left Ventricular Thrombus”
We appreciate the interest and feedback that our recently published article, “Effect of Duration of Anticoagulation in the Incidence of Stroke in Patients With Left Ventricular Thrombus,” has generated.1 In our study, we found that long-term anticoagulation (LTA,>12 months) was associated with lower risk of stroke than was short-term anticoagulation (STA) in a cohort of 98 patients with left ventricular thrombus (LVT). In a Letter to the Editor, in a large well-conducted study, Goh et al2 investigated the generalizability of the results in an Asian population , reporting no differences in the incidence of stroke in p...
Source: The American Journal of Cardiology - January 21, 2023 Category: Cardiology Authors: Álvaro Lorente-Ros, Gonzalo L. Alonso-Salinas, Juan M. Monteagudo Ruiz, José L. Zamorano Gómez Source Type: research
Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (From the Edoxaban Versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation ENSURE-AF Study)
In the ENSURE-AF study, edoxaban was compared to enoxaparin –warfarin in patients undergoing electrical cardioversion of nonvalvular atrial fibrillation, showing comparable low rates of bleeding and thromboembolism. This ancillary analysis investigated differences in relation to stroke and bleeding risk profiles. Secondly, we determined clinical risk profi les to quality of anticoagulation control in the warfarin arm. Primary efficacy (composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular death) and safety (composite of major and clinically relevant nonmajor bleeding) outcomes and time to...
Source: The American Journal of Cardiology - October 26, 2017 Category: Cardiology Authors: Gregory Y.H. Lip, Jose L. Merino, G. Andrei Dan, Sakis Themistoclakis, Kenneth A. Ellenbogen, Raffaele De Caterina, Assen Goudev, James Jin, Michael Melino, Shannon M. Winters, Andreas Goette Source Type: research
The CHA2DS2-VASc Score for Risk Stratification of Stroke in Heart Failure With-vs-Without Atrial Fibrillation
A recent study suggested that the CHA2DS2-VASc score can risk stratify heart failure (HF) patients without atrial fibrillation (AF) for stroke. We performed a retrospective analysis using the national Veteran Affairs database to externally validate the findings. Crude incidence rates of end points were calculated. A Cox proportional model was used to study the association between the CHA2DS2-VASc score and outcomes. In HF patients with AF (n = 17,481) and without AF (n = 36,935), the 1 year incidence rate for ischemic stroke, thromboembolism, thromboembolism (without MI), and death were 2.7 and 2.0%; 10.3 and 7.9%; 4....
Source: The American Journal of Cardiology - July 14, 2021 Category: Cardiology Authors: George R. Marzouka, Harold Rivner, Vijay Mehta, Juan Lopez, Igor Vaz, Fei Tang, Hemant Ishwaran, Jeffrey J. Goldberger Source Type: research
Effect of Duration of Anticoagulation in the Incidence of Stroke in Patients With Left-Ventricular Thrombus
The optimal duration of anticoagulation in patients with left-ventricular thrombus (LVT) is unclear. In the present study, we aimed to analyze the effect of treatment duration ( ≤12 months [short-term anticoagulation, (STA)] versus>12 months [long-term anticoagulation, (LTA)]) in the incidence of stroke and other secondary outcomes (acute myocardial infarction, bleeding, and mortality). Multivariate Cox regression was used to determine the association between treatment duration and stroke, adjusted for baseline embolic risk.
Source: The American Journal of Cardiology - October 12, 2022 Category: Cardiology Authors: Álvaro Lorente-Ros, Gonzalo L. Alonso-Salinas, Juan M. Monteagudo Ruiz, María Abellás-Sequeiros, José M. Vieítez-Florez, Diego Sánchez Vega, Jesús Álvarez-Garcia, Marcelo Sanmartín-Fernández, Marta Lorente-Ros, Susana del Prado Díaz, Covadonga Source Type: research
Effect of Anticoagulation Duration on Stroke Incidence in Asian Patients With Left Ventricular Thrombus
Left ventricular thrombus (LVT) occurs in acute myocardial infarction (AMI) and in ischemic and nonischemic cardiomyopathies.1,2 LVT may result in embolic stroke.3 We read with interest the study by Lorente-Ros et al4 published in the American Journal of Cardiology. That study, conducted in a Spanish cohort, found that prolonged anticoagulation>12 months for LVT was associated with lower stroke risk. We aimed to study the generalizability of these results in an Asian population because the original article was a single-center study with limited representation.
Source: The American Journal of Cardiology - January 24, 2023 Category: Cardiology Authors: Fang Qin Goh, Aloysius S.T. Leow, Jamie S.Y. Ho, Benjamin Y.Q. Tan, Leonard L.L. Yeo, Ching-Hui Sia Source Type: research
Meta-Analysis of Anticoagulation Use, Stroke, Thromboembolism, Bleeding and Mortality in Patients with Atrial Fibrillation on Dialysis
Atrial fibrillation (AF) is common in patients on dialysis. While randomized trials of anticoagulation for AF have demonstrated striking reductions in stroke, these trials did not recruit dialysis patients. We thus undertook this systematic review and meta-analysis of observational studies. Electronic databases were searched for studies including AF patients on dialysis that reported observational associations of anticoagulation use. Twenty-one studies involving 530,031 individuals and 31,611 AF patients on dialysis were identified.
Source: The American Journal of Cardiology - April 12, 2016 Category: Cardiology Authors: Christopher X. Wong, Ayodele Odutayo, Connor A. Emdin, Ned J. Kinnear, Michelle T. Sun Source Type: research
Economy Class Syndrome, patent foramen ovale and stroke
Whether or not air travel in a patient with patent foramen ovale (PFO) is a risk factor for cerebral embolism is unresolved. This is illustrated by a recent case report of the Massachusetts General Hospital in the New England Journal of Medicine of deep venous thrombosis and stroke associated with air travel. The discussant concluded that because of the relatively short flight “it seems unlikely that air travel was a major risk factor” 1. This may well be true for deep venous thrombosis per se, the risk of which has been shown to increase with duration of the flight 2.
Source: The American Journal of Cardiology - August 1, 2016 Category: Cardiology Authors: Franz H. Messerli, Stefano F. Rimoldi, Urs Scherrer Source Type: research
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
The safety of intravenous thrombolysis in patients taking rivaroxaban has not been well established. We retrospectively analyzed the outcomes of all patients who received thrombolytic therapy in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). A review of medical and adverse event records for patients receiving thrombolytic therapy while enrolled in ROCKET AF was performed to determine their baseline characteristics, indications for thrombolysis, and type of agent used.
Source: The American Journal of Cardiology - August 7, 2017 Category: Cardiology Authors: Sean T. Chen, Anne S. Hellkamp, Richard C. Becker, Scott D. Berkowitz, G ünter Breithardt, Keith A.A. Fox, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Daniel E. Singer, Manesh R. Source Type: research
Adverse Impact of Peri-Procedural Stroke in Patients Who Underwent Percutaneous Coronary Intervention
Peri-procedural stroke (PPS) is an important complication in patients who underwent percutaneous coronary intervention (PCI). The extent to which PPS impacts mortality and outcomes remains to be defined. Consecutive patients who underwent PCI enrolled in the Victorian Cardiac Outcomes Registry (2014 to 2018) were categorized into PPS and no PPS groups. The primary outcome was 30-day major adverse cardiovascular events (MACEs) (composite of mortality, myocardial infarction, stent thrombosis, and unplanned revascularization).
Source: The American Journal of Cardiology - August 20, 2022 Category: Cardiology Authors: Noah Z. Wexler, Sara Vogrin, Angela L. Brennan, Samer Noaman, Omar Al-Mukhtar, Kawa Haji, Jason E. Bloom, Diem T. Dinh, Wayne C. Zheng, James A. Shaw, Stephen J. Duffy, Jeffrey Lefkovits, Christopher M. Reid, Dion Stub, David M. Kaye, Nicholas Cox, Willia Source Type: research
Anticoagulant Agents for Atrial Fibrillation in Cancer Patients
In a recent article in the journal, Patell et al1 found CHADS2 (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism) and CHA2DS2VASC (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism, vascular disease, age 65-74, sex category [i.e., female]) to predict risk of ischemic stroke in cancer patients with baseline atrial fibrillation (AF). Although only 36% of patients received anticoagulant therapy, the risk of stroke generally appeared to be lower than in cancer-free individuals.
Source: The American Journal of Cardiology - February 3, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Mireia Santos-Gomez, Elisa Orna Source Type: research
Gender Differences of Thromboembolic Events in Atrial Fibrillation
Atrial fibrillation (AF) is the most common clinically relevant arrhythmia and increases the risk of thromboembolism and stroke; however, these risks are not the same for women and men. This review examines the evidence and clinical significance of increased thromboembolic risk in women with AF. The balance of results from over thirty recent studies suggests that female gender is an independent stroke risk factor in AF, and the inclusion of female gender in stroke risk stratification models, such as CHA2DS2-VASc, has improved risk assessment.
Source: The American Journal of Cardiology - December 31, 2015 Category: Cardiology Authors: Emily Y. Cheng, Melissa H. Kong Source Type: research
Dabigatran and Acute Coronary Syndromes
There has been considerable interest in the utility of newer oral anticoagulants for the secondary prevention of myocardial infarction (MI) and acute coronary syndromes (ACS). The direct thrombin inhibitor dabigatran has been approved for stroke prevention in patients with atrial fibrillation. However, as Verheugt discussed, when combined with dual antiplatelet therapy for secondary prevention in patients with ACS, no difference was found between the placebo and dabigatran groups for the composite end point of cardiovascular death, nonfatal MI, or stroke. However, it should also be noted that recent reports have actually ...
Source: The American Journal of Cardiology - May 1, 2013 Category: Cardiology Authors: John R. Kapoor Tags: Readers' Comments Source Type: research
Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome
In conclusion, until the results of additional ongoing or planned randomized trials are known, clinicians must continue to rely on expert opinion and their own clinical judgment when treating these patients.
Source: The American Journal of Cardiology - December 16, 2013 Category: Cardiology Authors: Daniel S. Ice, Timothy A. Shapiro, Eric M. Gnall, Peter R. Kowey Tags: Review Source Type: research
